Compare RTO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTO | JAZZ |
|---|---|---|
| Founded | 1925 | 2003 |
| Country | United Kingdom | Ireland |
| Employees | 64084 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 15.0B |
| IPO Year | N/A | 2007 |
| Metric | RTO | JAZZ |
|---|---|---|
| Price | $30.61 | $232.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $35.00 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 871.7K | 810.7K |
| Earning Date | 03-09-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.43 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $17.05 | $6.22 |
| Revenue Next Year | $4.35 | $7.68 |
| P/E Ratio | $222.16 | ★ $53.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.72 | $105.00 |
| 52 Week High | $34.67 | $243.32 |
| Indicator | RTO | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 54.77 |
| Support Level | $30.30 | $224.23 |
| Resistance Level | $32.12 | $242.66 |
| Average True Range (ATR) | 0.44 | 7.12 |
| MACD | 0.11 | -1.58 |
| Stochastic Oscillator | 55.64 | 48.45 |
Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in over 90 countries, with its largest operations in the United States following the acquisition of Terminix. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.